The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...
The medication offers relatively modest pain relief, underscoring the challenges of finding new ways to manage pain.
One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which she experienced when taking opioids.
It was given to people who had acute surgical pain from either abdominoplasty, also known as a tummy tuck, or bunion surgery.
The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or ...